Skip to main content

DP Technology

Category: AI in Healthcare

An 'AI for Science' research infrastructure platform leveraging deep learning to revolutionize molecular simulation for drug discovery and new materials development. DP Technology was founded in 2018. The company is led by Sun Weijie. Based in Beijing, China. Team size: 201-500. Total funding raised: $250.0M+. Latest round: Series C ($114.0M, Feb 2025). Key investors include ["Qiming Venture Partners","Source Code Capital","GL Ventures","MSA Capital","CATL"].

Founded
2018
Headquarters
Beijing, China
Team size
201-500
Total funding
$250.0M+

Value proposition

Solves the 'curse of dimensionality' by combining the accuracy of Quantum Mechanics with the speed of Molecular Dynamics (10,000x faster than traditional DFT methods).

Products and solutions

["Bohrium® (Scientific Cloud Computing Platform)","Hermite® (Computational Drug Design)","RiDYMO® (Dynamics-based Drug Discovery)","Piloteye® (Battery Design Automation)","Uni-Mol (3D Molecular Pre-trained Models)"]

Unique value

Pioneered the 'AI for Science' (AI4S) paradigm, integrating physical laws (first-principles) with deep learning to simulate atomic interactions with ab-initio accuracy at unprecedented scale.

Target customer

Pharmaceutical companies, New Energy/Battery manufacturers, Material Science firms, Academic research institutions

Industries served

["Biopharmaceuticals","New Energy (Batteries)","Material Science","Semiconductors","Academic Research"]

Technology advantage

Holders of the 'Deep Potential' method (2020 Gordon Bell Prize winner); developing 'Large Atomic Models' (LAM) to serve as foundation models for the physical world.

How they differentiate

Pioneered 'Deep Potential' algorithms that achieve quantum-level accuracy at molecular dynamics speed; offers a cross-domain 'AI for Science' infrastructure serving both biopharma and material science, unlike competitors focused primarily on bio.

Main competitors

["Schrödinger","XtalPi","Insilico Medicine"]

Key partnerships

["CATL (Battery Materials)","Lepu Biopharma (Drug Discovery)","Peking University (Academic)","DeepModeling Open Source Community"]

Notable customers

["CATL","Hansoh Pharmaceutical","Lepu Biopharma","Wuxi Biortus Biosciences"]

Major milestones

["Won the 2020 ACM Gordon Bell Prize","Launched Bohrium® Scientific Computing Platform in 2022","Secured strategic partnership with CATL","Raised $114M Series C in 2025"]

Growth metrics

Rapid adoption of Bohrium platform by academic and industrial users; partnered with industry leaders like CATL for material design.

Market positioning

Infrastructure builder for the 'AI for Science' (AI4S) paradigm; aiming to be the 'Android/OS' of scientific computing.

Geographic focus

China (HQ), expanding to North America and Europe

Patents and IP

Proprietary algorithms for Deep Potential Molecular Dynamics (DPMD) and specific applications in battery/drug screening.

About Sun Weijie

Sun Weijie is the Founder and CEO of DP Technology. He previously served as an Investment Manager at Will Hunting Capital (2016-2018) and holds the position of Executive Director at the Molecule Simulation Center of the Beijing Institute of Science and Intelligent Engineering. He holds a Master's degree in Educational Economy and Management and a Bachelor's in PPE from Peking University.

Official website: